Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone – Clinical Cases

INTRODUCTION: Cariprazine is a third-generation antipsychotic approved in Europe in 2017 for the treatment of schizophrenia. It presents distinct pharmacodynamic properties, such as D3/D2 partial agonism, preferential binding to D3 receptors, antagonism at the serotonin 5-HT2A and 5-HT2B receptors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Viegas, Filipa, Ferreira, Tiago, Campos, Cláudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192349/
https://www.ncbi.nlm.nih.gov/pubmed/35712695
http://dx.doi.org/10.2147/NDT.S343747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192349/
https://www.ncbi.nlm.nih.gov/pubmed/35712695
http://dx.doi.org/10.2147/NDT.S343747

Ejemplares similares